Q-omics provides the consensus-scored RPL7AP57 profile across patient tissues and cancer cell-line models. RPL7AP57 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, RPL7AP57 is differentially expressed in 1, with the highest sampling consensus in COAD. Additionally, RPL7AP57 RNA expression shows 5,537 significant pathway-activity associations, with the highest sampling consensus in UCEC. Together, these results highlight KIRC, COAD, and UCEC as cancer lineages where RPL7AP57 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPL7AP57 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPL7AP57 survival associations across molecular data types. RPL7AP57 RNA expression shows survival associations in the most cancer types (20). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPL7AP57 RNA expression–survival associations across cancer types. High RPL7AP57 expression shows unfavorable associations in KIRC, UCS, BRCA, DLBC and LUAD, but favorable associations in TGCT. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify KIRC as the clearest survival context for RPL7AP57 RNA expression.
This table summarizes RPL7AP57 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for RPL7AP57. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPL7AP57 shows higher tumor expression in COAD. The COAD box plot shows higher RPL7AP57 RNA expression in tumor versus normal tissue (log2 FC = +0.053, t-test p = .027).
This table shows molecular features associated with RPL7AP57 in patient tissues and cancer cell lines. In patient samples, RPL7AP57 shows the broadest associations at the RNA and protein expression levels, with UCEC recurring as the lineage with the largest associated feature set.
